Astonea Labs (544409)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 40.24% indicates product demand or revenue traction
• Latest quarter is profitable at ₹1 Cr net profit on ₹66 Cr sales
• ROCE of 17.30% suggests decent capital efficiency at the operating level
• Small market cap offers potential for high growth if business execution improves

Concerns

• Profit growth declined 33.33% despite a 40.24% sales increase, showing margin compression
• Net profit margin is extremely thin at around 1.5% in the latest quarter
• Piotroski F-Score of 4/9 indicates weak overall financial health
• Critical data missing: book value, debt/equity, promoter holding, and no dividend

AI Analysis

I’ve always said the first rule of investing is not to lose money, and the second rule is not to forget the first. Astonea Labs, at ₹158.50 with a market cap of just ₹167 Cr, makes me feel uncomfortable. Yes, sales grew 40.24%, but what good is a growing top line when profit growth is minus 33.33%? Look at the latest quarter: ₹66 Cr in sales produced only ₹1 Cr in net profit. That is a razor-thin 1.5% margin. A business that cannot convert sales into profits is not compounding my wealth; it is just consuming capital. At a P/E of 35.91, I am paying a rich price for earnings that are going backward. The PEG ratio of 0.89 looks cheap, but it is a trap because it seems to be based on sales growth, not real profit growth. Graham would demand a margin of safety; this share has none that I can measure. ROCE of 17.30% is respectable, but I cannot see book value, debt/equity, promoter holding, or a dividend. That is unacceptable for a shareholder. The Piotroski F-score of 4 out of 9 reinforces my concern about financial health. This may be an early turnaround story, but until margins improve and the balance sheet is transparent, this is not a business I can buy. I would wait, watch, and demand evidence of profitability before risking a rupee.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer